Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: News

You are here:
  1. Home
  2. Category "News"

Results of the Combined General Shareholders’ Meeting of June 30, 2021

2021By Alexis BERNARDJuly 1, 2021

01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021

Signature of an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib

2021By Alexis BERNARDJune 28, 2021

28/06/2021 – AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib

Results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting

2021By Alexis BERNARDJune 10, 2021

10/06/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting

Summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

2021By Alexis BERNARDJune 8, 2021

08/06/2021 – AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

Webcast presentation following the voluntary hold of clinical studies with masitinib

2021By adminJune 8, 2021

08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib

Live webcast on Thursday June 3, 2021 following the voluntary hold in the clinical studies of masitinib

2021By Alexis BERNARDJune 2, 2021

02/06/2021 – AB Science will host a live webcast on June 3, 2021 to provide details on the decision to suspend voluntarily the clinical studies with masitinib

AB Science announces a voluntary hold in the clinical studies of masitinib

2021By Alexis BERNARDJune 1, 2021

01/06/2021 – AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide

Results from Phase 3 study evaluating masitinib in prostate cancer

2021By Alexis BERNARDMay 26, 2021

26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021

Masitinib in Prostate Cancer Webcast Presentation

2021By adminMay 25, 2021

25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF

Live webcast on Tuesday May 25, 2021 on masitinib’s results in prostate cancer

2021By Alexis BERNARDMay 21, 2021

21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer

←1
2345678910
…1112131415…
16171819202122
23→
AB Science
© AB Science – All right reserved
Go to Top